CTOs on the Move

Magenta Therapeutics

www.magentatx.com

 
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune and blood based diseases.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.magentatx.com
  • 50 Hampshire Street 8th Floor
    Cambridge, MA USA 02139
  • Phone: 857.242.0170

Executives

Name Title Contact Details
David Nichols
Chief Technical Officer Profile

Funding

Magenta Therapeutics raised $48.5M on 11/17/2016
Magenta Therapeutics raised $50M on 05/02/2017
Magenta Therapeutics raised $52M on 04/09/2018
Magenta Therapeutics raised $86.4M on 05/12/2021

Similar Companies

Bedrocan

Bedrocan is an experienced producer of pharmaceutical-grade medicinal cannabis with over 13 years growing expertise in global markets. We provide patients and healthcare professionals with safe, effective and consistent medicine for the appropriate management of diagnosed health conditions. Our strains of pharmaceutical-grade cannabis are used by thousands of patients in seven countries, including Canada. We provide three fully standardized products, and as a result, our standardized strains are the choice for researchers and academics who study the medical effects of cannabis.

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.

Vivakor

Vivakor is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Creo

Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Founded in 2016 and based in California, Creo`s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet. Creo`s technology partner and major shareholder is industry-leading biotech firm Genomatica.

Beta Bionics

Beta Bionics is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet® Bionic Pancreas System. The iLet Bionic Pancreas is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body`s natural ability to maintain tight glycemic control. Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation™. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.